441 related articles for article (PubMed ID: 18057117)
1. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
2. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
4. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
5. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein.
Neuhaus W; Stessl M; Strizsik E; Bennani-Baiti B; Wirth M; Toegel S; Modha M; Winkler J; Gabor F; Viernstein H; Noe CR
Neurosci Lett; 2010 Jan; 469(2):224-8. PubMed ID: 19963040
[TBL] [Abstract][Full Text] [Related]
7. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
8. Effect of p-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells.
Yang ZY; Liu GQ
Pharmazie; 2004 Dec; 59(12):952-6. PubMed ID: 15638085
[TBL] [Abstract][Full Text] [Related]
9. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
[TBL] [Abstract][Full Text] [Related]
10. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
11. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
12. Rapid assessment of p-glycoprotein-drug interactions at the blood-brain barrier.
Bubik M; Ott M; Mahringer A; Fricker G
Anal Biochem; 2006 Nov; 358(1):51-8. PubMed ID: 16942742
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier.
He L; Zhao C; Yan M; Zhang LY; Xia YZ
Phytother Res; 2009 Jul; 23(7):933-7. PubMed ID: 19172664
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study.
Tsai PL; Tsai TH
Planta Med; 2004 Nov; 70(11):1069-74. PubMed ID: 15549664
[TBL] [Abstract][Full Text] [Related]
15. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
17. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.
Ishiwata K; Kawamura K; Yanai K; Hendrikse NH
J Nucl Med; 2007 Jan; 48(1):81-7. PubMed ID: 17204702
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
20. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
